Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis DOI Creative Commons

Yongjuan Wu,

Guangyuan Cheng,

Jun Han

и другие.

Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Май 16, 2025

Myosteatosis, characterized by fat infiltration into skeletal muscle, is increasingly recognized as a prognostic factor in hepatocellular carcinoma (HCC), although the results were not consistent. This meta-analysis aimed to summarize impact on overall survival (OS) and progression-free (PFS) patients with HCC.A systematic search of PubMed, Embase, Web Science was conducted identify observational studies reporting outcomes HCC without myosteatosis. Pooled hazard ratios (HRs) 95% confidence intervals (CIs) calculated using random-effects model. A total 24 retrospective cohort involving 7436 included. Myosteatosis significantly associated poorer OS (HR: 1.60, CI: 1.40-1.83, p < 0.001, I2 = 65%) PFS 1.53, 1.33-1.76, 36%). Subgroup analysis revealed stronger association Asian 1.74 for OS; 1.57 PFS) compared European 1.08 1.05 PFS). The remained significant regardless anticancer treatment type, myosteatosis assessment method, sex-specific or universal cutoff values, follow-up duration (p subgroup differences all > 0.05). adjusting sarcopenia 1.89 1.50 Meta-regression analyses did suggest any following variables may affect results, including sample size, mean ages patients, proportions men, durations, study quality scores 0.05).Myosteatosis independently worse particularly populations. These findings highlight significance assessing muscle HCC.

Язык: Английский

Myosteatosis and the survival of patients with hepatocellular carcinoma: a meta-analysis DOI Creative Commons

Yongjuan Wu,

Guangyuan Cheng,

Jun Han

и другие.

Clinical and Experimental Medicine, Год журнала: 2025, Номер 25(1)

Опубликована: Май 16, 2025

Myosteatosis, characterized by fat infiltration into skeletal muscle, is increasingly recognized as a prognostic factor in hepatocellular carcinoma (HCC), although the results were not consistent. This meta-analysis aimed to summarize impact on overall survival (OS) and progression-free (PFS) patients with HCC.A systematic search of PubMed, Embase, Web Science was conducted identify observational studies reporting outcomes HCC without myosteatosis. Pooled hazard ratios (HRs) 95% confidence intervals (CIs) calculated using random-effects model. A total 24 retrospective cohort involving 7436 included. Myosteatosis significantly associated poorer OS (HR: 1.60, CI: 1.40-1.83, p < 0.001, I2 = 65%) PFS 1.53, 1.33-1.76, 36%). Subgroup analysis revealed stronger association Asian 1.74 for OS; 1.57 PFS) compared European 1.08 1.05 PFS). The remained significant regardless anticancer treatment type, myosteatosis assessment method, sex-specific or universal cutoff values, follow-up duration (p subgroup differences all > 0.05). adjusting sarcopenia 1.89 1.50 Meta-regression analyses did suggest any following variables may affect results, including sample size, mean ages patients, proportions men, durations, study quality scores 0.05).Myosteatosis independently worse particularly populations. These findings highlight significance assessing muscle HCC.

Язык: Английский

Процитировано

0